It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Protein ubiquitination regulates a wide range of cellular processes. The degree of protein ubiquitination is determined by the delicate balance between ubiquitin ligase (E3)-mediated ubiquitination and deubiquitinase (DUB)-mediated deubiquitination. In comparison to the E3-substrate interactions, the DUB-substrate interactions (DSIs) remain insufficiently investigated. To address this challenge, we introduce a protein sequence-based ab initio method, TransDSI, which transfers proteome-scale evolutionary information to predict unknown DSIs despite inadequate training datasets. An explainable module is integrated to suggest the critical protein regions for DSIs while predicting DSIs. TransDSI outperforms multiple machine learning strategies against both cross-validation and independent test. Two predicted DUBs (USP11 and USP20) for FOXP3 are validated by “wet lab” experiments, along with two predicted substrates (AR and p53) for USP22. TransDSI provides new functional perspective on proteins by identifying regulatory DSIs, and offers clues for potential tumor drug target discovery and precision drug application.
The specificity of protein deubiquitination relies on deubiquitinase-substrate interactions (DSIs). Here, authors leverage evolutionary information from the proteome to predict DSIs, even with an inadequate training dataset.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Beijing Institute of Lifeomics, State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing, China (GRID:grid.419611.a) (ISNI:0000 0004 0457 9072)
2 Beijing Institute of Lifeomics, State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing, China (GRID:grid.419611.a) (ISNI:0000 0004 0457 9072); China Agricultural University, State Key Laboratory of Farm Animal Biotech Breeding, College of Biological Sciences, Beijing, China (GRID:grid.22935.3f) (ISNI:0000 0004 0530 8290)
3 Beijing Institute of Lifeomics, State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing, China (GRID:grid.419611.a) (ISNI:0000 0004 0457 9072); Anhui Medical University, School of Basic Medical Sciences, Hefei, China (GRID:grid.186775.a) (ISNI:0000 0000 9490 772X)
4 Beijing Institute of Lifeomics, State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing, China (GRID:grid.419611.a) (ISNI:0000 0004 0457 9072); Hebei University, College of Life Sciences, Baoding, China (GRID:grid.256885.4) (ISNI:0000 0004 1791 4722)